Global Breast Cancer Liquid Biopsy Market, By Product (Consumables, Kits), Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa), Industry Trends and Forecast to 2029.
Market Analysis and Insights of Breast Cancer Liquid Biopsy
Breast cancer liquid biopsy market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to grow at a CAGR of 23.09% in the above-mentioned forecast period.
Breast cancer liquid biopsy is basically the procedure of the detection in liquid blood sample extracted from the target cancerous site for tumor cells. This biopsy procedure generally helps to identify the cancerous biomarkers at an early stage to help in better treatments and health care services.
The factors such as the patients and physicians are enhancing their preferences for different forms of non-invasive healthcare services, whether those are treatments or diagnosis are the significant factors responsible for driving the growth of the breast cancer liquid biopsy market in the above-mentioned forecast period. In addition to this, with the implementation of liquid biopsy, the adoption and availability of personalized medicine is highly convenient and the increasing trend of developing personalized therapeutics also heighten the overall growth of the market in the forecast period of 2022 to 2029. On the other hand, the concerns in relation to clinical benefits associated with this form of diagnosis for cancer obstruct the market’s growth. Additionally, the lack of healthcare services in low-income countries is also estimated to hamper the market’s growth within the above mentioned forecast period.
The untapped emerging markets and growing technical developments are expected to generate profitable opportunities for the market in the forecast period of 2022 to 2029. On the flip side, the shortage of skilled professional have the potential to challenge for the market’s growth.
This breast cancer liquid biopsy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research breast cancer liquid biopsy market contact us for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Breast Cancer Liquid Biopsy Market Scope and Market Size
Breast cancer liquid biopsy market is segmented on the basis of product, circulating biomarkers and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of product, breast cancer liquid biopsy market has been segmented into consumables and kits.
- Breast cancer liquid biopsy market has been segmented on the basis of circulating biomarkers into extracellular vesicles (EVs), cell-free DNA (cfDNA), ctRNA, circulating tumor cells (CTCs), cfRNA and others. Others consist of cell-free protein biomarkers.
- Based on end users, breast cancer liquid biopsy market has been segmented into laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories and pathology laboratories.
Breast Cancer Liquid Biopsy Market Country Level Analysis
Breast cancer liquid biopsy market is analyzed and market size insights and trends are provided by product, circulating biomarkers and end users as referenced above.
The countries covered in the breast cancer liquid biopsy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the preference of the region to utilize various advanced diagnostic technologies amid availability of advanced healthcare infrastructure in the forecast period of 2022 to 2029. Asia-Pacific, on the other hand, is expected to show a rapid and lucrative growth rate in the forecast period owing to the focus of authorities on reducing the burden of healthcare diseases by implementing advanced technologies along with the significant rise of breast cancer prevalence in the region.
The country section of the breast cancer liquid biopsy market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
Breast cancer liquid biopsy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for breast cancer liquid biopsy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the breast cancer liquid biopsy market. The data is available for historic period 2010 to 2020.
Competitive Landscape and Breast Cancer Liquid Biopsy Market Share Analysis
Breast cancer liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to breast cancer liquid biopsy market.
Some of the major players operating in the breast cancer liquid biopsy market report are Johnson & Johnson Private Limited., Medtronic, QIAGEN, GUARDANT HEALTH., F. Hoffmann-La Roche Ltd, Menarini Silicon Biosystems, Thermo Fisher Scientific., Siemens, Biocept, Inc., Bio-Rad Laboratories, Inc., Fluxion Biosciences, Inc., Cynvenio AI, Inc., FOUNDATION MEDICINE, INC., Sysmex Inostics Inc, ExoDx, and Illumina, Inc. among others.
In 2020, Personalis, Inc., had launched the NeXT Liquid Biopsy, which is a high-performance, exome-scale, tumor-profiling platform that basically utilizes blood samples from advanced-stage solid tumor cancer patients.